SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cell Genesys (CEGE)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Bharat Kalra who started this subject8/24/2000 12:55:27 PM
From: Londo  Read Replies (1) of 1298
 
Anybody take a look at Transkaryotic (TKTX) lately?

As some of you may know, CEGE is entitled to a high single digit percentage of royalties that TKTX will earn on their sales of gene-activated EPO. Problem is that AMGN is suing TKTX, claiming they have a patent.

But recent stock performance of TKTX suggests that more of the market is betting on TKTX, which is an implicit positive indicator for CEGE.

If TKTX can win, CEGE has basically earned their first real revenue source - without actually releasing a product out on the market.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News